PMID- 22974419
OWN - NLM
STAT- MEDLINE
DCOM- 20130528
LR  - 20191112
IS  - 1875-5631 (Electronic)
IS  - 1566-5232 (Linking)
VI  - 12
IP  - 6
DP  - 2012 Dec
TI  - Growth responses following a single intra-muscular hGH plasmid administration 
      compared to daily injections of hGH in dwarf mice.
PG  - 437-43
AB  - In previous work, sustained levels of circulating human growth hormone (hGH) and 
      a highly significant weight increase were observed after electrotransfer of naked 
      plasmid DNA (hGH-DNA) into the muscle of immunodeficient dwarf mice (lit/scid). 
      In the present study, the efficacy of this in vivo gene therapy strategy is 
      compared to daily injections (5 mug/twice a day) of recombinant hGH (r-hGH) 
      protein, as assessed on the basis of several growth parameters. The slopes of the 
      two growth curves were found to be similar (P > 0.05): 0.095 g/mouse/d for 
      protein and 0.094 g/mouse/d for DNA injection. In contrast, the weight increases 
      averaged 35.5% (P < 0.001) and 23.1% (P < 0.01) for protein and DNA 
      administration, respectively, a difference possibly related to the 
      electroporation methodology. The nose-to-tail linear growth increases were 15% 
      and 9.6% for the protein and DNA treatments, respectively, but mouse insulin-like 
      growth factor I (mIGF-I) showed a greater increase over the control with DNA (5- 
      to 7-fold) than with protein (3- to 4-fold) administration. The weight increases 
      of several organs and tissues (kidneys, spleen, liver, heart, quadriceps and 
      gastrocnemius muscles) were 1.3- to 4.6-fold greater for protein than for DNA 
      administration, which gave a generally more proportional growth. Glucose levels 
      were apparently unaffected, suggesting the absence of effects on glucose 
      tolerance. A gene transfer strategy based on a single hGH-DNA administration thus 
      appears to be comparable to repeated hormone injections for promoting growth and 
      may represent a feasible alternative for the treatment of growth hormone 
      deficiency.
FAU - Higuti, Eliza
AU  - Higuti E
AD  - Biotechnology Department, National Nuclear Energy Commission (IPEN-CNEN), Cidade 
      Universitaria, Sao Paulo, SP, Brazil.
FAU - Cecchi, Claudia R
AU  - Cecchi CR
FAU - Oliveira, Nelio A J
AU  - Oliveira NA
FAU - Vieira, Daniel P
AU  - Vieira DP
FAU - Jensen, Thomas G
AU  - Jensen TG
FAU - Jorge, Alexander A L
AU  - Jorge AA
FAU - Bartolini, Paolo
AU  - Bartolini P
FAU - Peroni, Cibele N
AU  - Peroni CN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Gene Ther
JT  - Current gene therapy
JID - 101125446
RN  - 0 (Blood Glucose)
RN  - 0 (Recombinant Proteins)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Dwarfism/drug therapy/metabolism
MH  - Electroporation
MH  - Gene Transfer Techniques
MH  - Genetic Therapy/*methods
MH  - Heart/drug effects/*growth & development
MH  - Human Growth Hormone/administration & dosage/genetics/*pharmacology
MH  - Humans
MH  - Injections, Intramuscular
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Kidney/drug effects/*growth & development
MH  - Liver/drug effects/*growth & development
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, SCID
MH  - Organ Size
MH  - Plasmids/*administration & dosage
MH  - Recombinant Proteins/administration & dosage/pharmacology
MH  - Spleen/drug effects/growth & development
MH  - Time Factors
MH  - Weight Gain
EDAT- 2012/09/15 06:00
MHDA- 2013/05/29 06:00
CRDT- 2012/09/15 06:00
PHST- 2012/03/21 00:00 [received]
PHST- 2012/07/04 00:00 [revised]
PHST- 2012/07/06 00:00 [accepted]
PHST- 2012/09/15 06:00 [entrez]
PHST- 2012/09/15 06:00 [pubmed]
PHST- 2013/05/29 06:00 [medline]
AID - CGT-EPUB-20120911-2 [pii]
AID - 10.2174/156652312803519797 [doi]
PST - ppublish
SO  - Curr Gene Ther. 2012 Dec;12(6):437-43. doi: 10.2174/156652312803519797.